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Abstract 
Introduction: Streptococcus agalactiae (group B streptococcus, GBS) is a recognized urinary pathogen both in males and pregnant or non-
pregnant women. Data regarding GBS serotypes recovered from urinary tract infections (UTIs) are scarce. The aim of this study was to describe 
the clinical and microbiological characteristics of UTIs caused by GBS in adult patients in Argentina. 
Methodology: A prospective multicenter study involving 86 centers was conducted in Argentina between July 1st, 2014 and June 30th, 2015. 
Antimicrobial susceptibility and serotype distribution of GBS isolated from the urinary tract of adult patients were determined. Susceptibility 
tests were performed by the disk diffusion and/or agar dilution methods. Epidemiological and clinical characteristics of the patients were 
considered to identify associated comorbilities. 
Results: Seven hundred and one GBS were sent to the reference laboratory in the above mentioned period, however, only 211 fulfilled our 
selection criteria (demographic data availability, underlying diseases reported, colony counts greater than 105 CFU/mL, single organism isolated 
from the urine sample). No penicillin-resistant GBS was found but fluoroquinolone resistance was high (12.8%), especially among GBS isolated 
from men and non-pregnant women. UTIs due to GBS were associated to underlying diseases in men and non-pregnant women, particularly 
diabetes mellitus. Most of the isolates showed serotypes Ia and III. 
Conclusions: GBS are still susceptible to penicillin but fluoroquinolone resistance is a growing concern, at least in Argentina. There are 
underlying conditions that could be associated to urinary infections caused by GBS. 
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Introduction 
For the last four decades it has been known that 
Streptococcus agalactiae, also called group B 
streptococcus (GBS), is responsible for urinary tract 
infections (UTIs) in adult patients [1] and bacteriuria in 
pregnant women [2,3]. GBS is also the cause of other 
conditions, such as cystitis, pyelonephritis and 
urosepsis, with neurogenic bladder as a potential risk 
factor. In addition, a rare invasive infection has been 
described in one patient suffering from an unusual, 
massive abdominopelvic abscess secondary to acute 
GBS UTI [4]. 
The incidence of genitourinary infections due to 
GBS increased at the end of the last century [5]. GBS 
accounts for up to 2% of UTIs, and 4.5% of involved 
patients with type II diabetes mellitus [6,7]. 
It is known that different serotypes can be found in 
different regions. Serotype distribution also varies 
depending on the anatomical location of the infections.  
Data regarding GBS serotypes recovered from UTIs 
is scarce [8]. Therefore, we decided to study the 
epidemiology of UTIs due to GBS in adult patients in 
the context of a one-year multicenter study, involving 
86 health centers of Argentina. Specifically, we aimed 
to analyze the clinical characteristics of the enrolled 
patients such as age, gender, predisposing condition and 
underlying diseases. We also studied the serotypes and 
the antimicrobial susceptibility of GBS circulating in 
our country. 
 




The present work was a prospective, multicenter 
observational study of UTIs due to GBS carried out 
from July 1st, 2014 to June 30th, 2015, in which 86 
health centers of 32 Argentinian cities participated 
(Figure 1). The data analyzed here represent all patients 
who presented significantly positive urine cultures (≥ 
105 CFU/mL of GBS) during the period studied. 
 
Patients and samples 
All adult patients (> 16 years of age) showing at 
least one sample of urine with ≥ 105 CFU/mL of GBS, 
collected by the midstream clean-catch technique, were 
included in this study. CAMP and latex agglutination 
tests were used to identify isolates to the species level. 
All non-pregnant patients were symptomatic, while 
pregnant women (PW) were either symptomatic or 
asymptomatic. Patient data were obtained from their 
clinical charts. 
The cases without accompanying complete clinical 
data (age, gender or pregnancy status) were excluded, 
as well as those cases with colony counts less than 105 
CFU/mL or without available colony count number, or 
instances in which GBS were isolated from a 
polymicrobial culture or those organisms that had been 
erroneously identified as GBS but belonged to other 
species. 
Urine samples were cultured following the current 
procedures used in each center. 
Urine pellets were obtained by centrifuging the 
urine samples for 10 minutes at 2,000 rpm. White blood 
cell (WBC) counts were considered significant if they 
were higher than 5 WBCs per high power field (HPF). 
 
Antimicrobial susceptibility tests 
Antimicrobial susceptibility to levofloxacin (LEV) 
and norfloxacin (NOR) was tested by the disk diffusion 
method according to CLSI guidelines. The screening 
for susceptibility to penicillin (PEN) was performed 
based on the scheme proposed by Kimura et al. [9] 
using oxacillin (OXA), ceftibuten (CBT) and 
ceftizoxime (CZX) disks and interpreted in accordance 
with their criteria. The interpretation of results for NOR 
was performed using the breakpoints of the Societé 
Francaise de Microbiologie [10] and those for LEV by 
using CLSI breakpoints [11]. 
MICs of PEN, erythromycin (ERY), clindamycin 
(CLI) and LEV were obtained by using the agar dilution 
method according to CLSI guidelines [12]. Phenotypes 
were characterized by the D test [12]. 
 
Serotyping 
Serotyping was performed by latex agglutination 




VassarStats was used to determine 95% confidence 
intervals and p-values using a chi-square test of 
association according to Yates’correction or the 
Fisher’s test, as required. 
 
Ethics approval 
This study fulfilled the requirements for a low risk 
research (National Health and Medical Research 
Figure 1. Health center distribution (32 cities). 
* 25/44 centers belong to the Federal District (Buenos Aires City); The 
map source is “source =Argentina Blank Map.svg”. 
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Council, NHMRC, 2015). Ethics approval was 
provided by the Ethics Committee of the Faculty of 
Pharmacy and Biochemistry, Universidad de Buenos 
Aires, Res (D) N4467/14. 
 
Results 
Background and clinical characteristics 
Seven hundred and one adult patients were studied 
during the above mentioned period. According to 
previous criteria, the total number of cases included 
were 211. Patients were stratified in males (M) (n = 28), 
non-pregnant women (NPW) (n = 104) and pregnant 
women (PW) (n = 79). 
An equal number of GBS obtained from mid stream 
clean-catch urine samples from adult patients (> 16 
years of age) were isolated and characterized. 
Underlying conditions are listed in Table 1. As 
expected, M and NPW showed more underlying 
diseases than PW. Diabetes mellitus was the most 
frequent comorbidity associated with UTIs due to GBS. 
Cardiovascular diseases were also frequently found, 
among which, arterial hypertension is one of the most 
common conditions, also associated with normal aging. 
Age distribution was bimodal for NPW with peaks 
in the elderly (> 50 y-o) and younger patients (16 - 30 
y-o) and not so defined for M. As expected , most PW 
showed ages between 16 and 30 y-o (Figure 2). 
 
Urine pellet results 
WBC counts ≥ 5 WBC/HPF in urine samples from 
M (28/32; 87.50%) and NPW (101/123; 82.11%) were 
significantly higher than those from PW (33/86; 
38.37%), (p ≤ 0.05). 
 
Antimicrobial susceptibility 
Antimicrobial susceptibility to LEV and NOR was 
tested for 194 isolates by using the disk diffusion 
method. LEV and NOR resistance was observed in 
12.8% of the tested isolates as a whole, while significant 
differences (p < 0.05) were found between M and NPW 
(16.0 and 18.7%) with respect to PW (3.8%), (Table 2).  
MICs of PEN, ERY, CLI and LEV were obtained 
by using the agar dilution method. A hundred eighty 
eight isolates were tested for susceptibility to PEN, 194 
isolates to fluoroquinolones and 182 to macrolides. 
All GBS tested were susceptible to PEN (MIC90 = 
0.06 µg/mL, MIC50 = 0.03 µg/mL, range ≤ 0.015 
µg/mL - 0.06 µg/mL) despite some false positive results 
using the screening test of Kimura et al. on 188 isolates. 
CBT yielded more false positive results than CZX and 
OXA (Table 2). 
ERY resistance rate (R + I) was 25.3% (46/182) 
while the CLI resistance rate was 13.19% (24/ 182). The 
prevalent phenotype was cMLSB with 10.99% (20/182), 
followed by iMLSB with 4.95% (9/182), M with 3.85% 
(7/182) and L with 2.2% (4/182). 
 
Table 1. Underlying conditions of adult patients with UTI due to GBS. 
Underlying conditions Males 
Non-pregnant 
women 
Pregnant women Total 
Diabetes mellitus 6 8 1 15 
Malignancy 3 4 0 7 
Cardiovascular disease 2 10 0 12 
Renal or urologic pathology 5 2 0 7 
Central nervous system condition 0 2 0 2 
Gastrointestinal complaint 0 2 1 3 
Others 1 7 0 8 
Without data 8 33 18 59 
None 5 44 59 108 
One predisposing condition 13 19 2 34 
More than one 2 8 0 10 
Total 28 104 79 211 
 
Figure 2. Age distribution of adult patients with UTI due to 
GBS. 
NPW: non-pregnant women, M: males, PW: pregnant women. 
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Serotyping 
One hundred ninety one isolates could be serotyped. 
Serotype Ia was the most frequent one among the GBS 
isolated from UTIs in adult patients (41.36%). Serotype 
III was detected more frequently among PW than in 
NPW (p < 0.05) (Table 3). 
Globally, serotypes Ia, Ib, and III, accounted for 
85.3% of the isolates. Serotypes IV, VI, VII, VIII, and 
IX were not found among these 191 GBS isolates. A 
significant association between serotype Ib and 
fluoroquinolone resistance was found (p < 0.001). No 




The importance of this study lies in the 
representativeness of the epidemiological data on the 
spread of GBS bacteria throughout the country. Prior to 
this study, GBS serotypes and antimicrobial 
susceptibility were seldom described by a few centers 
and often focalized in a limited number of invasive or 
colonizing isolates. 
It is remarkable that, despite the limitations of this 
study (bias due to lack of information of several 
patients), M and NPW frequently presented underlying 
conditions, especially diabetes mellitus. 
GBS continued to be susceptible to PEN in 
Argentina. Fluoroquinolone resistance (12.8%) was 
higher than in the latest reports from our country and 
even from other countries of Latin America and the rest 
of the world, except Korea [13] and China, where the 
prevalence is near 50% in isolates recovered from UTIs 
[14]. The fluoroquinolone resistance rate found in this 
study was similar to that determined in invasive GBS 
isolates obtained from the same centers in a study of 
invasive disease caused by GBS conducted by our 
group during the same period (unpublished results). 
GBS isolates recovered from NPW and M were 
significantly more resistant to fluoroquinolones than 
those isolated from PW. The cause of this difference 
might be that these antibiotics are not used for the 
treatment of infections in PW. However, it may also be 
associated with the clonal spread of a fluoroquinolone-
resistant strain among NPW and/or M, an issue that will 
be further investigated. 
 Studies reporting antimicrobial resistance of GBS 
recovered from UTIs are scarce. In Brazil, ERY and 
CLI resistance rates vary from 5% to 19%, while in 







Ceftibuten < 20 178 (94.7) 
PEN 
< 0.03 – 0.06 
Oxacillin < 17 8 (4.2) 
Ceftizoxime < 29 17 (9.0) 





Levofloxacin (total) < 17 b 24 (12.8) 
Levofloxacin (PW) *, ** < 17 b 3/78  (3.8) 
Levofloxacin (NPW)* < 17 b 17/91 (18.7) 
LEV M ** < 17 b 4/25 (16.0) 
Breakpoint: below this breakpoint for each antibiotic, the isolate is considered resistant; a Committee of the antibiogram of the French Society of Microbiology. 
(2015), b Clinical and Laboratory Standards Institute (2015); *chi square, Yates: p = 0.005; ** Fisher: p = 0.05. 
Table 3. GBS Serotypes isolated from the urinary tract of adult patients. 
Serotype 
Urinary tract isolates (%) 
Total 
N (%) 
M NPW PW 
Ia 79 (41.36) 10 36 33 
Ib 25 (13.09) 2 16 7 
II 6 (3.14) 1 4 1 
III 59 (30.89) 8 20 31 
IV 0 0 0 0 
V 14 (7.33) 4 5 5 
VI 0 0 0 0 
VII 0 0 0 0 
VIII 0 0 0 0 
IX 0 0 0 0 
NT 8 (4.19) 0 5 3 
Total 191 25 86 80 
NPW: non-pregnant women, M: males, PW: pregnant women. 
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USA, ERY resistance was observed in 39.5% of the 
isolates [7,15,16]. In the present study, almost 25% 
resistance to ERY was detected, half of which was 
associated with resistance to CLI. Considering that 
different studies were carried out in different time 
periods, it is difficult to reliably compare our scenario. 
We can only say that the observed resistance to CLI and 
ERY does not differ much from that found in Brazil 
[16] and Turkey [17] and that it is slightly lower than 
that reported in the USA [7]. 
In a recent Brazilian study [18], CLI resistance 
levels in bacteriuria were reported to be slightly lower 
(9.3%) than those herein detected; however, ERY 
resistance was considerably lower (11.3%). Notably, no 
LEV-resistant strains were detected. The level of LEV 
resistance in strains from adult patients in our country 
(12.8%) is alarming and should be an incentive for 
neighbouring regions to continue an active screening of 
fluoroquinolone sensitivity. 
Serotypes Ia, III and Ib (in this order) were the most 
frequently recorded among GBS from the urinary tract, 
while serotypes, Ia, Ib, V and III (in this order) were 
prevalent in invasive isolates obtained during the same 
period (unpublished results). Serotype III was 
especially more frequently found in GBS from PW than 
in the isolates from NPW. 
 Serotype distribution differs from that reported in 
Brazil [16,18]. In a study of bacteriuria samples, the 
prevalent serotype was V, followed by Ia, II and III. In 
a recent study of symptomatic urinary tract infections, 
serotype V was also prevalent, followed by II, Ia and 
III. This difference in serotype distribution emphasizes 
the importance of gaining awareness about the current 
status of regional epidemiology. 
 
Conclusion 
UTIs due to GBS were associated to underlying 
diseases in M and NPW, especially diabetes mellitus. 
Serotypes Ia and III were the most prevalent among the 
isolates studied. GBS are still susceptible to penicillin 
but fluoroquinolone resistance is a growing health 
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